Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Journal of the American Heart Association|October 29, 2021
Pragmatic Weight Management Program for Patients With Obesity and Heart Failure With Preserved Ejection FractionElia C El Hajj, Milad C El Hajj, Brandon Sykes, et al.
Journal of Telemedicine and Telecare|July 27, 2018
Description, utilisation and results from a telehealth primary care weight management intervention for adults with obesity in South CarolinaJoshua D Brown, Sarah Hales, T Ed Evans, et al.
Obesity (Silver Spring, Md.)|March 17, 2012
Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM studyPatrick M O'Neil, Steven R Smith, Neil J Weissman, et al.
Eating Behaviors|January 14, 2014
Changes in cardiovascular risk factors with participation in a 12-week weight loss trial using a commercial formatVanessa A Milsom, Robert J Malcolm, Gail C Johnson, et al.
Translational Behavioral Medicine|September 3, 2021
Pilot evaluation of a personalized commercial program on weight loss, health outcomes, and quality of lifeSarah B Hales, Erica M Schulte, Tonya F Turner, et al.
Obesity (Silver Spring, Md.)|November 3, 2016
Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical MarkersKen Fujioka, Patrick M O'Neil, Melanie Davies, et al.
Archives of Medical Research|November 23, 2024
Genetic Risk Phenotypes for Type 2 Diabetes Differ with Ancestry in US Adults with Diabetes and Overweight/ObesityLauren A Fowler, José R Fernández, Patrick M O'Neil, et al.
Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery|September 20, 2011
Socially desirable responding by bariatric surgery candidates during psychological assessmentSuman Ambwani, Abbe G Boeka, Joshua D Brown, et al.
Diabetes, Obesity & Metabolism|April 8, 2017
Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trialsPatrick M O'Neil, Vanita R Aroda, Arne Astrup, et al.
Obesity (Silver Spring, Md.)|July 9, 2025
Long-acting PYY3 -36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studiesBirgitte S Wulff, Adam Paul Chambers, Cynthia Karenina Osorto Contreras, et al.
Pageof 6